Curriculum Vitæ. Università degli Studi di URBINO "Carlo BO" - Via A. Saffi, 2 - URBINO

Transcript

1 Curriculum Vitæ Informazioni personali Nome RUZZO Annamaria Indirizzo Dipartimento Scienze Biomolecolari Urbino ( PU) Telefono Fax annamaria.ruzzo@uniurb.it Cittadinanza ITA Data di nascita 26/07/1962 Titoli di studio Data di conseguimento Titolo conseguito Titolo della Tesi Titolo dottorato 13/02/2006 Dottore di ricerca POLIMORFISMI GENETICI E SUSCETTIBILITÀ INDIVIDUALE AL RISCHIO DI CARCINOMA GASTRICO Metodologie biochimiche e farmacologiche Data di conseguimento 27/06/1986 Titolo conseguito Laurea (vecchio ordin.) Descrizione Scienze Biologiche Voto conseguito 108/110 STUDIO DEI MARKERS DELLE SOTTOPOPOLAZIONIE DELLE FUNZIONI DEI Titolo della Tesi LINFOCITI NEL SANGUE PERIFERICO IN UN GRUPPO DI SOGGETTI CON ABITUDINI AL FUMO Esperienze Periodo Posizione Qualifica Struttura Periodo Posizione Qualifica 02/05/ oggi Dipendente tecnico-amministrativo Posizione economica D2 Dip. SCIENZE BIOMOLECOLARI 01/10/ oggi Professore a contratto Professore a contratto - 1 -

2 Struttura Biochimica Computazionale e Bioinformatica Dip. SCIENZE BIOMOLECOLARI Periodo 01/01/ /06/2009 Posizione Attività didattica Qualifica Professore a contratto master II livello in Biotecnologie - Bioinformatica Struttura Dip. SCIENZE BIOMOLECOLARI Periodo 01/01/ /06/2008 Posizione Attività didattica Qualifica Professore a contratto master II livello in Biotecnologie Bioinformatica Struttura Dip. SCIENZE BIOMOLECOLARI Periodo 01/01/ /06/2007 Posizione Attività didattica Qualifica Professore a contratto master II livello in Biotecnologie Bioinformatica Struttura Ist. Chimica biologica Periodo 01/01/ /06/2006 Posizione Attività didattica Qualifica Professore a contratto master I livello in Biotecnologie Bioinformatica Struttura Ist. Chimica biologica Periodo 01/01/ /06/2005 Posizione Attività didattica Qualifica Professore a contratto master I livello in Biotecnologie Bioinformatica Struttura Ist. Chimica biologica Periodo 01/01/ /06/2004 Posizione Attività didattica Qualifica Professore a contratto - 2 -

3 Struttura master I livello in Biotecnologie Bioinformatica Ist. Chimica biologica Periodo 05/04/ /04/2004 Posizione Tirocinio o stage Qualifica Tirocinante o stagista Bioinformatics Essential Course King's College London - - Strand Periodo 01/01/ /06/2003 Posizione Attività didattica Qualifica Professore a contratto master I livello in Biotecnologie Bioinformatica Struttura Ist. Chimica biologica Periodo 01/01/ /12/2002 Posizione Cultore della materia Qualifica Cultore della materia Corso Genetica I e Genetica II Struttura Ist. Chimica biologica Periodo 08/07/ /07/2002 Posizione Tirocinio o stage Qualifica Tirocinante o stagista Short Course in Computational Biology University of Michigan - - Periodo 01/01/ /06/2002 Posizione Professore a contratto Qualifica Professore a contratto master I livello in Biotecnologie Bioinformatica Struttura Ist. Chimica biologica Periodo 14/11/ /11/2001 Posizione Tirocinio o stage Qualifica Tirocinante o stagista - 3 -

4 Tipo 2nd Course In Bioinformatics European School of Genetic Medicine Bertinoro - Ente di ricerca privato italiano Periodo 01/01/ /06/2001 Posizione Professore a contratto Qualifica Professore a contratto master I livello in Biotecnologie Bioinformatica Struttura Ist. Chimica biologica Periodo 01/01/ /06/2000 Posizione Professore a contratto Qualifica Professore a contratto master I livello in Biotecnologie Struttura Ist. Chimica biologica Periodo 01/01/ /05/2000 Posizione Attività didattica Qualifica Professore a contratto Corso Integrativo all'insegnamento di Biologia Generale Periodo 05/07/ /07/1999 Posizione Tirocinio o stage Qualifica Tirocinante o stagista Fondazione per le Biotecnologie Torino. Training Course For Gene Transfer In Animals.Villa Gualino Torino Università degli Studi di TORINO - Via Verdi, 8 - TORINO Periodo 01/03/ /04/1999 Posizione Attività didattica Qualifica Professore a contratto Corso Integrativo all'insegnamento di Biologia Generale Periodo 01/01/ /12/1998 Posizione Cultore della materia Qualifica Cultore della materia insegnamento di Biologia Generale - 4 -

5 Struttura Ist. Chimica biologica Periodo 01/03/ /04/1998 Posizione Professore a contratto Qualifica Professore a contratto Corso Integrativo all'insegnamento di Biologia Generale Periodo 28/07/ /08/1994 Posizione Tirocinio o stage Qualifica Tirocinante o stagista Human Genome Analysis: From YAC To Gene UMDS Guys Hospital London Bridge London. Wellcome Summer School - Tipo Ente di ricerca straniero Periodo 17/11/ /06/1989 Posizione Borsista Società italiana medicina perinatale Struttura Ist. Chimica biologica Periodo 01/02/ /09/1988 Posizione Borsista Struttura Ist. Chimica biologica Periodo 06/04/ /04/1988 Posizione Tirocinio o stage Qualifica Tirocinante o stagista Scuola di Genetica - "European School of Medical Genetics" organizzata dalla Federation of European Biochemical Societies e International School of Pediatric Science. ISTITUTO GIANNINA GASLINI (IRCCS) - Via Gerolamo Gaslini, 5 - GENOVA Periodo 15/09/ /03/1987 Posizione Tirocinio o stage Qualifica Tirocinante o stagista Tirocinio post-laurea per biologi legge 28/10/1982 n.980 Struttura Ist. Chimica biologica Elenco dei - 5 -

6 prodotti della ricerca F. Loupakis, C. Cremolini, D. Yang, L. Salvatore, W. Zhang, T. Wakatsuki, P. Bohanes, M. Schirripa, L. Benhaim, S. Lonardi, C. Antoniotti, G. Aprile, F. Graziano, RUZZO A, S. Lucchesi, M. Ronzoni, F. De Vita, G. Tonini, A. Falcone, H-J Lenz (2013). Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLOS ONE, vol. 8, ISSN: , doi: /journal.pone RUZZO A, F. Galli, E. Giacomini, I. Floriani, E Rulli, F. Galli, S. Lonardi, B. Massidda, N. Pella, C. Mucciarini, R. Labianca, E. Veltri, P. Sozzi, S. Barni, E. Pasquini, A. Sobrero, L. Frontini, M. Magnani, F. Graziano (2013). PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL. In: -. Milano, ottobre Il Pensiero Scientifico, vol. 14 (1) october E.Melucci, A.Torsello, RUZZO A, I.Sperduti, E.Giacomini, M.Zeuli, A.Gelibter, V.Ferraresi, M.G.Diodoro, M.Magnani, M.Mottolese, F.Cognetti, C.Garufi (2013). Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts). In: -. Chicago, May 31-June , vol. 31 (suppl; abstr e22206) VINCENZI B, SANTINI D, PERRONE G, GRAZIANO F, LOUPAKIS F, SCHIAVON G, FREZZA, AM, RUZZO A, RIZZO S, CRUCITTI P, GALLUZZO S, ZOCCOLI A, RABITTI C, MUDA AO, RUSSO A, FALCONE A, TONINI G (2012). PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.. JOURNAL OF CELLULAR PHYSIOLOGY, vol. 227; p , ISSN: , doi: /jcp C.Cremolini, F.Loupakis, D.Yang, L.Salvatore, W.Zhang, T.Wakatsuki, M.Schirripa, S.Leonardi, C.Antoniotti, M.Casagrande, G.Aprile, G.Masi, F.Graziano, RUZZO A, S.Lucchesi, M.Ronzoni, M.K.H.Maus, G.Bocci, G.Tonini, H.J.Lenz, A.Falcone (2012). Prospective evaluation of - 6 -

7 candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mcrc) patients treated with first-line folfiri plus bevacizumab (BV). In: -. Roma, ottobre 2012Il pensiero scientifico, vol. 13(3), p. S25- RUZZO A, F.Galli, I.Floriani, E.Rulli, V.Zagonel, S.Lonardi, M.Ronzoni, B.Massidda, N.Pella, C.Mucciarini, R.Labianca, P.Ziranu, E.Veltri, P.Sozzi, S.Barni, V.Ricci, L.Foltran, E.Pasquini, A.Nuzzo, A.Bramati, D.Turci, S.Lazzarelli, C.Verusio, F.Bergamo, E.Giacomini, A.Sobrero, L.Frontini, M.Magnani, F.Graziano (2012). Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial. In: -. Roma, ottobre 2012-, vol. 13(3), p. S26- C.Antoniotti, F.Loupakis, C.Cremolini, W.Zhang, D.Yang, T.Wakatsuki, M.Schirripa, L.Salvatore, V.Ricci, F.Graziano, G.Masi, RUZZO A, S.E.Lutrino, M.J.Labonte, Y.Ning, R.El-Khoueriry, A.Falcone, H.J.Lenz (2012). Prospective Study of EGFR Intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan. In: -. Roma, ottobre 2012-, vol. 13(3), p. S28- RUZZO A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M. (2012). High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. THE ONCOLOGIST, vol. 17; p , ISSN: Cremolini C, Loupakis F, Yang D, Salvatore L, Zhang W, Wakatsuki T, Schirripa M, Lonardi S, Antoniotti C, Aprile G, Masi G, Graziano F, RUZZO A, Lucchesi S, Ronzoni M, Maus M K H, Bocci G, Tonini G, Falcone A, Lenz H (2012). Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mcrc) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). JOURNAL OF CLINICAL ONCOLOGY, vol. 30 (suppl; abstr 3518), ISSN: X Antoniotti C, Loupakis F, Cremolini C, Zhang W, Yang D, Wakatsuki T, Schirripa M, Salvatore S, Ricci V, Graziano F, Masi G, RUZZO A, Labonte M J, Ning Y, El-Khoueiry R, - 7 -

8 Falcone A, Lenz H-J (2012). Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan. JOURNAL OF CLINICAL ONCOLOGY, vol. 30 (suppl; abstr 3540), ISSN: X GRAZIANO F, GALLUCCIO N, LORENZINI P, CATALANO V, ANDREONI F, LIGORIO C, CANESTRARI E, SISTI V, RUZZO A, D' EMIDIO S, DI OTO E, RULLI E, FIORENTINI G, ZINGARETTI C, DE NICTOLIS M, CAPPUZZO F (2011). MET COPY NUMBER GAIN IMPACTS ON PROGNOSIS OF HIGH RISK GASTRIC CANCER PATIENTS. I SUPPLEMENTI DI TUMORI, vol. 11 CANESTRARI E, RUZZO A, VINCENZI B, GALLUCCIO N, PERRONE G, ANDREONI F, LORENZINI P, RULLI E, D'EMIDIO S, CATALANO V, LOUPAKIS F, BISONNI R, FLORIANI I, DE NICTOLIS M, SANTINI D, SALVATORE L, TONINI G, FALCONE A, MAGNANI M, GRAZIANO F (2011). Let-7a microrna levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-egfr. JOURNAL OF CLINICAL ONCOLOGY, ISSN: X GALLUCCIO N, RUZZO A, CANESTRARI E, LORENZINI P, D'EMIDIO S, SISTI V, CATALANO V, ANDREONI F, ZINGARETTI C, DE NICTOLIS M, LIGORIO C, CAPPUZZO F, MAGNANI M, GRAZIANO F (2011). C-MET gene copy number variation (CNV) analysis by quantitative PCR (qpcr) assay in Caucasian patients with gastric cancer (GC). JOURNAL OF CLINICAL ONCOLOGY, vol. suppl; abstr 4038, ISSN: X Graziano F, Galluccio N, Lorenzini P, RUZZO A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M (2011). Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. JOURNAL OF CLINICAL ONCOLOGY, vol. 29; p , ISSN: X Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, RUZZO A, Falcone A, Francini G, Dicuonzo G, Tonini G (2011). Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer - 8 -

9 treatment in KRAS wild-type advanced colorectal cancer patients. ANNALS OF ONCOLOGY, vol. 22; p , ISSN: Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, RUZZO A, Vincenzi B, Graziano F, Loupakis F, Falcone A, Muda AO, Tonini G (2011). Should oncologists be aware in their clinical practice of KRAS molecular analysis?. JOURNAL OF CLINICAL ONCOLOGY, vol. 29, ISSN: X Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, RUZZO A, Canestrari E, Magnani M, Falcone A (2011). Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 78; p , ISSN: RUZZO A, Canestrari E, Galluccio N, Santini D, Vincenzi B, Tonini G, Magnani M, Graziano F. (2011). Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. ANNALS OF ONCOLOGY, vol. 22; p , ISSN: RUZZO A, VINCENZI B, CANESTRARI E, PERRONE G, GALLUCCIO N, LORENZINI P, RULLI E, CATALANO V, LOUPAKIS F, BISONNI R, RABITTI C, DE NICTOLIS M, SANTINI D, SALVATORE L, TONINI G, GIUSTINI L, FALCONE A, MAGNANI M, GRAZIANO F (2011). LET-7a MICRO-RNA LEVELS IN KRAS MUTATED COLORECTAL CARCINOMAS IMPACT ON SURVIVAL OF PATIENTS TREATED WITH SALVAGE CETUXIMAB. I SUPPLEMENTI DI TUMORI, vol. 11 LOUPAKIS F, RUZZO A, SALVATORE L, CREMOLINI C, MASI G, FRUMENTO P, SCHIRRIPA, M, CATALANO V, GALLUCCIO N, CANESTRARI E, VINCENZI B, SANTINI D, BENCARDINO K, RICCI V, MANZONI M, DANOVA M, TONINI G, MAGNANI M, FALCONE A, GRAZIANO F. (2011). Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line - 9 -

10 FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC CANCER, vol. 11, ISSN: , doi: / RUZZO A, E. CANESTRARI, N. GALLUCCIO, V. CATALANO, D. SANTINI, F. LOUPAKIS, P. ALESSANDRONI, D. SPADA, R. FICARELLI, S. DEMIDIO, B. VINCENZI, M. ROCCHI, S.ANGELETTI, S.GALLUZZO, L. SALVATORE, C. CREMOLINI, G. TONINI, A. FALCONE, M. MAGNANI, F. GRAZIANO (2010). Host genetic variants in the Insulin Growth Factor Binding Protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. In: Clin Chem Lab Med. Santorini, Greece, 30 settembre- 2 ottobrede GRUYTER, vol. 48(8), p. A72, ISBN/ISSN: ISSN , doi: /CCLM BALDI GG, FORNARO L, MASI G, VASILE E, LOUPAKIS F, CUPINI S, ALLEGRINI G, MARCUCCI L, STASI I, SANTINI D, TONINI G, GRAZIANO F, RUZZO A, MAGNANI M, FALCONE A (2010). CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-RESISTANT ELDERLY METASTATIC COLORECTAL CANCER PATIENTS: CLINICAL OUTCOME ACCORDING TO KRAS AND BRAF MUTATIONAL STATUS. In:?. BARCELLONA, 30 GIUGNO 3 LUGLIO, doi: /annonc/mdq269 D. SANTINI, F. LOUPAKIS, E. CANESTRARI, N. SILVESTRIS, B. VINCENZI, F. GRAZIANO, G. COLUCCI, A. FALCONE, G. TONINI, RUZZO A (2010). Correlation of BRAF wild-type status (WT) in primary colorectal tumors with BRAF status in related metastatic sites: Implications for treatment with anti-egfr antibodies. In: 2010 Gastrointestinal Cancers Symposium B. VINCENZI, S. GALLUZZO, D. SANTINI, L. ROCCI, F. LOUPAKIS, P. CORREALE, R. ADDEO, A. ZOCCOLI, F. GRAZIANO, RUZZO A, S. DEL PRETE, A. FALCONE, G. FRANCINI, G. DICUONZO, G. TONINI (2010). EARLY MAGNESIUM MODIFICATIONS AS A SURROGATE MARKERS OF EFFICACY OF CETUXIMAB BASED ANTICANCER TREATMENT IN ADVANCED COLORECTAL CANCER PATIENTS (A6). TUMORI, vol. 10_1, ISSN:

11 Cremolini C, RUZZO A, Graziano F, Falcone A, Loupakis F (2010). Reply: KRAS status analysis and anti-egfr therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. BRITISH JOURNAL OF CANCER, ISSN: , doi: /sj.bjc RUZZO A, Graziano F, Canestrari E, Magnani M (2010). Molecular predictors of efficacy to anti-egfr agents in colorectal cancer patients. CURRENT CANCER DRUG TARGETS, vol. 10; p , ISSN: Graziano F, RUZZO A, Canestrari E, Catalano V, Santini D, Galluccio N, Loupakis F, Alessandroni P, Spada D, Ficarelli R, Bisonni R, D'Emidio S, Vincenzi B, Angeletti S, Salvatore L, Cremolini C, Tonini G, Falcone A, Magnani M (2010). Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. PHARMACOGENOMICS, vol. 11; p , ISSN: , doi: /pgs Cremolini C, Loupakis F, RUZZO A, Perrone G, Rulli E, Vincenzi B, Tonini G, Graziano F, Muda AO, Falcone A (2010). Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?. JOURNAL OF CLINICAL ONCOLOGY, vol. 28, ISSN: X F.Graziano, E.Canestrari, F.Loupakis, RUZZO A, N.Galluccio, D.Santini, M.Rocchi, B.Vincenzi, L.Salvatore, C.Cremolini, C.Spoto, V.Catalano, S.D'Emidio, P.Giordani, G.Tonini, A.Falcone, M.Magnani (2010). Genetic modulation of the Let-7 microrna binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. PHARMACOGENOMICS JOURNAL, vol. 10; p , ISSN: X Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, RUZZO A (2010). High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. ANNALS OF ONCOLOGY, vol. 21, ISSN:

12 LOUPAKIS F, RUZZO A, CREMOLINI C, VINCENZI B, SALVATORE L, SANTINI D, MASI G, STASI I, CANESTRARI E, RULLI E, FLORIANI I, BENCARDINO K, GALLUCCIO N, CATALANO V, TONINI G, MAGNANI M., FONTANINI G, BASOLO F, FALCONE A, GRAZIANO F (2009). KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. BRITISH JOURNAL OF CANCER, vol. 101(4); p , ISSN: GRAZIANO F, RUZZO A, CANESTRARI E, LOUPAKIS F, SANTINI D, RULLI E, HUMAR B, GALLUCCIO N, BISONNI R, FLORIANI I, MALTESE P, FALCONE A, TONINI G, CATALANO V, FONTANA A, GIUSTINI L, MASI G, VINCENZI B, ALESSANDRONI P, MAGNANI M. (2009). Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. PHARMACOGENOMICS JOURNAL, vol. 9(1); p , ISSN: X RUZZO A, CREMOLINI C, LOUPAKIS F, FORNARO L, SANTINI D, VINCENZI B, CANESTRARI E, MAGNANI M, FALCONE A, GRAZIANO F (2009). Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients. In: J Clin Oncol 27:15s, 2009 (suppl; abstr 4058). Orlando, FL USA, 29 maggio-2 giugno MALTESE P, CANESTRARI E, PALMA L, RUZZO A, CORINI F, MENOTTA M, ANDREONI F, LATIANO A, ANNESE V, MAGNANI M. (2009). High resolution melting (HRM) analysis for the detection of ER22/23EK, BcII, and N363S polymorphisms of the glucocorticoid receptor gene. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 113; p , ISSN: ANGELETTI S, GALLUZZO S, SANTINI D, RUZZO A, VINCENZI B, FERRARO E, SPOTO C, LORINO G, GRAZIANO N, CALVIERI A, MAGNANI M., GRAZIANO F, PANTANO F, TONINI G, DICUONZO G (2009). NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian

13 population. HUMAN IMMUNOLOGY, vol. 70; p , ISSN: LOUPAKIS F, POLLINA L, STASI I, RUZZO A, SCARTOZZI M, SANTINI D, MASI G, GRAZIANO F, CREMOLINI C, RULLI E, CANESTRARI E, FUNEL N, SCHIAVON G, PETRINI I, MAGNANI M., TONINI G, CAMPANI D, FLORIANI I, CASCINU S, FALCONE A (2009). PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol. 27; p , ISSN: , doi: /JCO RUZZO A, CREMOLINI C, LOUPAKIS F, FORNARO L, SANTINI D, VINCENZI B, CANESTRARI E, MAGNANI M, FALCONE A, GRAZIANO F (2009). Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients.. Orlando, FL, USA, 29 Maggio-2 Giugno 2009 LOUPAKIS F, CREMOLINI C, PERRONE G, STASI I, SALVATORE L, VINCENZI B, RUZZO A, RONZONI M, BENCARDINO K, FALCONE A. (2009). Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mcrc) patients. In: J Clin Oncol 27:15s, (suppl; abstr 4021). Orlando, FL USA, 29 MAGGIO-2 GIUGNO VINCENZI B, PERRONE G, SANTINI D, LOUPAKIS F, FRANCESCO, GRAZIANO, RUZZO A, VENDITTI O, ONETTI MUDA A, FALCONE A, TONINI G (2009). PML AS A POTENTIAL PREDICTIVE FACTOR OF EFFICACY OF OXALIPLATIN BASED FIRST LINE CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS. In: Annals of Oncology 20 (Supplement 8): session L: gastrointestinal, doi: /ANNONC/MDP445 NEGRI F, BOZZETTI C, LAGRASTA C, CRAFA P, GRAIANI G, NALDI N, BORTESI B, AZZONI C, RUZZO A, CAMISA R, BONASONI MP, BISAGNI G, ARDIZZONI A (2009). PTEN EXPRESSION IN ADVANCED COLORECTAL CANCER TREATED WITH CETUXIMAB. In: Annals of

14 Oncology 20 (Supplement 8): session L: gastrointestinal, doi: /annonc/mdp445 CREMOLINI C, LOUPAKIS F, PERRONE G, RUZZO A, RULLI E, GARAVAGLIA D, BENCARDINO K, FORNARO L, VINCENZI B, STASI I, MASI G, SANTINI D, VASILE E, SALVATORE L, BALDI GG, SPOTO C, TONINI G, FLORIANI I, GRAZIANO F, FALCONE A (2009). BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILDTYPE METASTATIC COLORECTAL CANCER (MCRC) PATIENTS. In: Annals of Oncology 20 (Supplement 8): session L: gastrointestinal, doi: /annonc/mdp445 RUZZO A, LOUPAKIS F, CANESTRARI E, CREMOLINI C, VINCENZI B, SALVATORE L, SANTINI D, MASI G, STASI I, RULLI E, FLORIANI I, BENCARDINO K, GALLUCCIO N, DEMIDIO S, CATALANO V, TONINI G, MAGNANI M, FALCONE A, GRAZIANO F (2009). KRAS CODON 61, 146 AND BRAF V600E MUTATIONS PREDICT RESISTANCE TO CETUXIMAB PLUS IRINOTECAN IN KRAS CODON 12 AND 13 WILD-TYPE METASTATIC COLORECTAL CANCER. In: Annals of Oncology 20 (Supplement 8): session L: gastrointestinal, doi: /ANNONC/MDP445 GRAZIANO F, CANESTRARI E, LOUPAKIS F, RUZZO A, SANTINI D, GALLUCCIO N, VINCENZI B, SALVATORE L, CREMOLINI C, SPOTO C, SCHIRRIPA M, CATALANO V, DEMIDIO S, GIORDANI P, ALESSANDRONI P, FALCONE A, TONINI G, MAGNANI M (2009). GENETIC MODULATION OF THE LET-7 MICRO-RNA BINDING TO KRAS 3 -UNTRANSLATED REGION (3 -UTR) IMPACTS ON SURVIVAL OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH UNRESPONSIVE DISEASE TO SALVAGE CETUXIMAB-IRINOTECAN. In: Annals of Oncology 20 (Supplement 8) session C: translational, doi: /ANNONC/MDP439 LOUPAKIS F, RUZZO A, SALVATORE L, CANESTRARI E, CREMOLINI C, MASI G, SCHIRRIPA M, SPOTO C, GALLUCCIO N, VINCENZI B, SANTINI D, BENCARDINO K, RICCI V, CATALANO V, MANZONI M, DANOVA M,

15 TONINI G, MAGNANI M, FALCONE A, GRAZIANO F (2009). VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS). In: Annals of Oncology 20 (Supplement 8): session L: gastrointestinal. milano, ottobre, doi: /annonc/mdp445 SANTINI D, LOUPAKIS F, VINCENZI B, PERRONE G, GRAZIANO F, FLORIANI IE, MALTESE P, STASI I, CANESTRARI E, MASI G, ONETTI MUDA A, MAGNANI M, FALCONE A, RUZZO A, TONINI G (2008). K-Ras status in primary colorectal tumours correlate with K-ras status in related metastatic sites: implications for treatment with anti-egfr antibodies in clinical setting. In: X Congresso Nazionale di Oncologia Medica X Congresso Nazionale AIOM. Verona, OTTOBRE LOUPAKIS F, STASI I, POLLINA L, RUZZO A, MASI G, CREMOLINI C, FUNEL N, FORNARO L, BALDI GG, SALVATORE L, CUPINI S, PETRINI I, SCARTOZZI M, FLORIANI I, SANTINI D, CASCINU S, RICCI S, TONINI G, MAGNANI M, FALCONE A (2008). PTEN EXPRESSION AND K-RAS MUTATIONS AS PREDICTORS OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS). In: X Congresso Nazionale di Oncologia Medica X Congresso Nazionale AIOM. Verona, OTTOBRE. LOUPAKIS F, FORNARO L, GRAZIANO F, SANTINI D, CREMOLINI C, STASI I, BALDI GG, SALVATORE L, VASILE E, MASI G, CUPINI S, CANESTRARI E, RUZZO A, VINCENZI B, TONINI G, MAGNANI M, FALCONE A (2008). BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients. In: VI Congresso Nazionale COMU: Cure palliative e terapie di supporto. Firenze, Dicembre GRAZIANO F, RUZZO A, LOUPAKIS F, CANESTRARI E, SANTINI D, CATALANO V, BISONNI R, TORRESI U, FLORIANI I, SCHIAVON G, ANDREONI F, MALTESE P, RULLI E, HUMAR B, FALCONE A, GIUSTINI L, TONINI G,

16 FONTANA A, MASI L, MAGNANI M. (2008). Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, vol. 26 (9); p , ISSN: X SANTINI D, ANGELETTI S, RUZZO A, DICUONZO G, GALLUZZO S, VINCENZI B, CALVIERI A, PIZZAGALLI F, GRAZIANO N, FERRARO E, LORINO G, ALTOMARE A, MAGNANI M, GRAZIANO F, TONINI G (2008). Toll-like receptor 4 Asp299Gly and Thr399Iie polymorphisms in gastric cancer of intestinal and diffuse histotypes. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 154; p , ISSN: MALTESE P, CANESTRARI E, RUZZO A, GRAZIANO F, FALCONE A, LOUPAKIS F, TONINI G, SANTINI D, MAGNANI M. (2008). VEGF gene polymorphisms and susceptibility to colorectal cancer disease in italian population. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol. 24 (2), ISSN: PERRONE G, RUFFINI PA, CATALANO V, SPINO C, SANTINI D, MURETTO P, SPOTO C, ZINGARETTI C, SISTI V, ALESSANDRONI P, GIORDANI P, CICETTI A, D'EMIDIO S, MORINI S, RUZZO A, MAGNANI M., TONINI G, RABITTI C, GRAZIANO F (2008). Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. EUROPEAN JOURNAL OF CANCER, vol. 44 (13); p , ISSN: VINCENZI B, PATTI G, GALLUZZO S, PANTANO F, VENDITTI O, SANTINI D, RUZZO A, SCHIAVON G, CARAGLIA M, MARRA M, GRAZIANO F, TONINI G (2008). Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: Results from a meta-analysis. ONCOLOGY REPORTS, vol. 20 (5); p , ISSN: X MURETTO P, RUZZO A, PIZZAGALLI F, GRAZIANO F, MALTESE P, ZINGARETTI C, BERSELLI E, DONNARUMMA N, MAGNANI M (2008). Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of

17 diffuse gastric cancer patients. ANNALS OF ONCOLOGY, vol. 19(3); p , ISSN: GRAZIANO F, RUZZO A, LOUPAKIS F, SANTINI D, CATALANO V, CANESTRARI E, MALTESE P, BISONNI R, FORNARO L, BALDI G, MASI G, FALCONE A, TONINI G, GIORDANI P, ALESSANDRONI P, GIUSTINI L, VINCENZI B, MAGNANI M. (2008). Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. BRITISH JOURNAL OF CANCER, vol. 99 (5); p , ISSN: NASRI S, MORE H, GRAZIANO F, RUZZO A, WILSON E, DUNBIER A, MCKINNEY C, MERRIMAN T, GUILFORD P, MAGNANI M., HUMAR B (2008). A novel diffuse gastric cancer susceptibility variant in E-caderin(CDH1) intron 2: A case control study in an Italian population. BMC CANCER, vol. 8; p. 138-, ISSN: SANTINI D, LOUPAKIS F, VINCENZI B, FLORIANI I, STASI I, CANESTRARI E, RULLI E, MALTESE PE, ANDREONI F, MASI G, GRAZIANO F, BALDI GG, SALVATORE L, RUSSO A, PERRONE G, TOMMASINO MR, MAGNANI M., FALCONE A, TONINI G, RUZZO A (2008). High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. THE ONCOLOGIST, vol. 13 (12); p , ISSN: Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, RUZZO A, Magnani M, Tonini G, Rabitti C, Graziano F (2008). Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. EUROPEAN JOURNAL OF CANCER, vol. 14; p , ISSN: MURETTO P, RUZZO A, PIZZAGALLI F, GRAZIANO F, DONNARUMMA N, MAGNANI M (2008). Endogastric capsule for E-cadherin gene (CDH1) promoter Hypermethylation assessment in DNA from gastric juice of

18 patients with gastric cancer. In: 1st International Conference on Drug Design and Discovery. DUBAI UAE, February 4-7 E. CANESTRARI, F. GRAZIANO, RUZZO A, F. ANDREONI, F. LOUPAKIS, E. RULLI, I. STASI, D. SANTINI, A. FALCONE, G. TONINI, M. MAGNANI (2008). Combined analysis of the KRAS status and the EGFR intron-1 polymorphism in colorectal carcinomas: Association with clinical outcomes to salvage irinotecan-cetuximab and first-line chemotherapy in patients with metastatic disease. In: 2008 Molecular Markers SANTINI D, LOUPAKIS F, VINCENZI B, FLORIANI I, STASI I, MALTESE P, FALCONE A, MAGNANI M, TONINI G, RUZZO A (2008). K-RAS STATUS IN PRIMARY COLORECTAL TUMOURS CORRELATE WITH K-RAS STATUS IN RELATED METASTATIC SITES: IMPLICATIONS FOR TREATMENT WITH ANTI-EGFR ANTIBODIES IN CLINICAL SETTING. In: 33rd ESMO Stokholm Stoccolma, SEPTEMBER 2008 LOUPAKIS F, POLLINA L, RUZZO A, MASI G, CREMOLINI C, SCARTOZZI M, FLORIANI I, SANTINI D, CASCINU S, FALCONE A (2008). ANALYSIS OF PTEN EXPRESSION AND KRAS MUTATIONS ON PRIMARIES (PRIM) AND METASTASES (METS) TO PREDICT BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS). In: 33rd ESMO Stokholm Stoccolma, SEPTEMBER 2008 RUZZO A, GRAZIANO F, LOUPAKIS F, RULLI E, CANESTRARI E, SANTINI D, CATALANO V, FICARELLI R, MALTESE P, BISONNI R, MASI G, SCHIAVON G, GIORDANI P, GIUSTINI L, FALCONE A, TONINI G, SILVA R, MATTIOLI R, FLORIANI I, MAGNANI M (2007). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, vol. 25; p , ISSN: X MORE H, HUMAR B, WEBER W, WARD R, CHRISTIAN A, LINTOTT C, GRAZIANO F, RUZZO A, ACOSTA E, BOMAN B, HARLAN M, FERREIRA P, SERUCA R, SURIANO G,

19 GUILFORD P (2007). Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. HUMAN MUTATION, vol. 28; p. 203-, ISSN: RUZZO A, GRAZIANO F, LOUPAKIS F, SANTINI D, CATALANO V, BISONNI R, FICARELLI R, FONTANA A, ANDREONI F, FALCONE A, CANESTRARI E, TONINI G, MARI D, LIPPE P, PIZZAGALLI F, SCHIAVON G, ALESSANDRONI P, GIUSTINI L, MALTESE P, TESTA E, MENICHETTI E T, MAGNANI M. (2007). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. PHARMACOGENOMICS JOURNAL, vol. 8; p , ISSN: X RUZZO A, CANESTRARI E, MALTESE P, PIZZAGALLI F, GRAZIANO F, SANTINI D, CATALANO V, FICARELLI R, MARI D, BISONNI R, GIORDANI P, GIUSTINI L, LIPPE P, SILVA R, MATTIOLI R, TORRESI U, LATINI L, MAGNANI M. (2007). Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol. 45; p , ISSN: VINCENZI B, PATTI G, PANTANO F, VENDITTI O, SANTINI D, RUZZO A, SCHIAVON G, GRAZIANO F, TONINI G (2007). Polymorphism of interleukin-1b and development of gastric cancer: a Metanalysis, October. In: Annals of Oncology. Palermo, october, vol. 18 GRAZIANO F, RUZZO A, LOUPAKIS F, FLORIANI I, CANESTRARI E, SANTINI D, CATALANO V, TORRESI U, BISONNI R, MASI G, SCHIAVON G, ANDREONI F, MALTESE P, GIUSTINI L, FALCONE A, TONINI G, RULLI E, FONTANA A, MARI D, MAGNANI M (2007). Pharmacogenetic profiling for anti-epidermal Growth Factor Receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC). In: ANNALS OF ONCOLOGY. PALERMO, OCTOBER, vol. 18 MURETTO P, STACCIOLI MP, RUZZO A, GRAZIANO F (2006). Endogastric capsule (EC) for molecular analysis of Helicobacter pylori (HP) infection and gastric ph. In: ANN

20 ONCOL. BARCELONA, SPAIN, 8 JUNE - 1 JULY, vol. 17, p. VI32-VI108 RUZZO A, CATALANO V, BISONNI R, LOUPAKIS F, CANESTRARI E, SANTINI D, FICARELLI R, MARI D, MALTESE P, SCHIAVON G, PIZZAGALLI F, MASI G, SAFINA V, GIORDANI P, LIPPE P, ALESSANDRONI P, GIUSTINI L, FALCONE A, TONINI G, SILVA RR, MATTIOLI R, MENICHETTI ET, TESTA E, LAI V, MAGNANI M.. GRAZIANO F (2006). PREDICTIVE ROLE OF A PHARMACOGENETIC PROFILING IN PATIENTS WITH ADVANCED COLORECTAL CANCER (ACRC) TREATED WITH FIRST-LINE, 5-FLUOROURACIL/IRINOTECAN CHEMOTHERAPY. In: ANNALS OF ONCOLOGY. MILANO, Novembre, vol. 17, p. xi41-xi42 RUZZO A, F. GRAZIANO, F. PIZZAGALLI, E. CANESTRARI, P. MALTESE, F. LOSCOCCO, M. MAGNANI (2006). Polymorphisms of DNA repair genes and individual susceptibility to Gastric Cancer. In: CCLM JOURNAL, SEPT 29-OCT 2, vol. 44 N.8, p. A73 GRAZIANO F, KAWAKAMI K, RUZZO A, WATANABE G, SANTINI D, PIZZAGALLI F, BISONNI R, MARI D, FLORIANI I, CATALANO V, SILVA R, TONINI G, TORRI V, GIUSTINI L, MAGNANI M. (2006). Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk italian population. INTERNATIONAL JOURNAL OF CANCER, vol. 118 (3); p , ISSN: RUZZO A, GRAZIANO F, KAWAKAMI K, WATANABE G, SANTINI D, CATALANO V, BISONNI R, CANESTRARI E, FICARELLI R, MENICHETTI E T, MARI D, TESTA E, SILVA R, VINCENZI B, GIORDANI P, CASCINU S, GIUSTINI L, TONINI G, MAGNANI M. (2006). Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, vol. 24(12); p , ISSN: X, doi: /JCO RUZZO A, GRAZIANO F, PIZZAGALLI F, SANTINI D,

21 BATTISTELLI V, PANUNZI S, CANESTRARI E, CATALANO V, HUMAR B, FICARELLI R, BEARZI I, CASCINU S, NALDI N, TESTA E, MAGNANI M. (2005). Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. ANNALS OF ONCOLOGY, vol. 16 (6); p , ISSN: GRAZIANO F, RUZZO A, SANTINI D, HUMAR B, TONINI G, CATALANO V, BERARDI R, PIZZAGALLI F, ARDUINI F, BEARZI I, SCARTOZZI M, CASCINU S, TESTA E, FICARELLI R, MAGNANI M. (2005). Prognostic role of Interleukin-1B Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients with Advanced Gastric Cancer. JOURNAL OF CLINICAL ONCOLOGY, vol. 23 (10); p , ISSN: X GRAZIANO F, RUZZO A (2005). Role of the interleukin-1 receptor antagonist gene polymorphism (IL-1RN*2) in early gastric cancer. JOURNAL OF CLINICAL ONCOLOGY, vol. 23(22); p , ISSN: X KAWAKAMI K, GRAZIANO F, WATANABE G, RUZZO A, SANTINI D, CATALANO V, BISONNI R, ARDUINI F, BEARZI I, CASCINU S, MURETTO P, PERRONE G, RABITTI C, GIUSTINI L, TONINI G, PIZZAGALLI F, MAGNANI M (2005). Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. CLINICAL CANCER RESEARCH, vol. 11(10); p , ISSN: K. KAWAKAMI, F. GRAZIANO, G. WATANABE, RUZZO A, D. SANTINI, V. CATALANO, R. BISONNI, R. FICARELLI, S. CASCINU, M. MAGNANI (2005). Prognostic role of Thymidylate Synthase (TS) gene polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. In: Journal of Clinical Oncology,. Vol,, 2005, vol. 23 RUZZO A, PIZZAGALLI F, GRAZIANO F, SANTINI D, CATALANO V, FICARELLI R, MENICHETTI, T, SCARROZZI M, CASCINU S, TESTA E, TONINI G, MAGNANI M, ESMO VIENNA POSTER (2005). ANALYSIS OF POLYMORPHISMS IN THE INTERLEUKIN-1BETA

22 GENE (IL-1B) AND IN THE INTERLEUKIN-1 RECEPTOR ANATAGONIST GENE (IL-1RN) FOR GASTRIC CANCER SUSCEPTIBILITY IN HELICOBACTER PYLORI (HP) NEGATIVE, ITALIAN PATIENTS. A REPORT. In: Ann. Onc. Jun. Vienna, Austria, 29 October - 2 November 2004, vol. 16, p GRAZIANO F, KAWAKAMI K, RUZZO A, SANTINI D, PIZZAGALLI F, BISONNI R, MARI D, FLORIANI I, CATALANO V, TESTA E, CASCINU S, GIULIODORI L, TONINI G, TORRI V, GIUSTIZI L, MAGNANI M, SILVA R R (2005). Methylenetetrahydrofolate Reductase 677C/T Gene (MTHFR 677C/T) Polymorphism, Gastric Cancer Risk And Genomic DNA Hypomethlation. A Report From The Italian Group For Genetic Research in Gastric Cancer. In: ANNALS OF ONCOLOGY. BARI, JUNE, vol. 16 GRAZIANO F, ARDUINI F, RUZZO A, BEARZI I, HUMAR B, MORE H, SILVA R, MURETTO P, GUILFORD P, TESTA E, MARI D, MAGNANI M., CASCINU S (2004). Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer. CLINICAL CANCER RESEARCH, vol. 10 (8); p , ISSN: F. GRAZIANO, F. ARDUINI, RUZZO A, I. BEARZI, B. HUMAR, H. MORE, P. GUILFORD, E. TESTA, V. CATALANO, S. CASCINU (2004). Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. In: Journal of Clinical Oncology, Proceedings (Post-Meeting Edition). No 14S (July 15 Supplement), 2004: 9632, vol. 22 GRAZIANO F, MANDOLESI A, RUZZO A, BEARZI I, TESTA E, ARDUINI F, SILVA R, MURETTO P, MARI D, BERARDI R, SCARTOZZI M, LAI V, CASCINU S, MAGNANI M. (2004). Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy. TUMOR BIOLOGY, vol. 25 (3); p , ISSN: GRAZIANO F, KAWAKAMI K, WATANABE G, RUZZO A, HUMAR B, SANTINI D, CATALANO V, FICARELLI R,

23 MERRIMAN T, PANUNZI S, TESTA E, CASCINU S, BEARZI I, TONINI G, MAGNANI M. (2004). Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility. INTERNATIONAL JOURNAL OF CANCER, vol. 112 (6); p , ISSN: GRAZIANO F, KAWAKAMI K, WATANABE G, RUZZO A, SANTINI D, CATALANO V, FICARELLI R, HUMAR B, MERRIMAN T, GUILFORD P, TESTA E, GALIZIA E, MAGNANI M, CASCINU S (2004). Association of Thymidylate Synthase Polymorphisms With Gastric Cancer Susceptibility. In: ANNALS OF ONCOLOGY. BOLOGNA, SEPTEMBER, vol. 15, p GRAZIANO F, ARDUINI F, RUZZO A, MANDOLESI A, BEARZI I, SILVA R, MURETTO P, TESTA E, MARI D, MAGNANI M., SCARTOZZI M, CASCINU S (2004). Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. ANNALS OF ONCOLOGY, vol. 15 (3); p , ISSN: RUZZO A, GRAZIANO F, COSTAGLIOLA A, ARDUINI F, TESTA E, BEARZI I, CORTESE G, DE GAETANO A, ANDREONI F, LAI V, MAGNANI M. (2003). The G/A Nucleotide Change at cdna Position 2494 in the E-Cadherin Gene (CDH1): Analysis in Italian Patients. TUMOR BIOLOGY, vol. 24 (3); p , ISSN: GRAZIANO F, RUZZO A, BEARZI I, TESTA E, LAI V, MAGNANI M. (2003). Screening E-cadherin germline mutations in italian patients with familial diffuse gastric cancer: an anlysis in the district of Urbino, Region Marche, Central Italy. TUMORI, vol. 89 (3); p , ISSN: RUZZO A, SPINO C, GRAZIANO F, TESTA E, COSTAGLIOLA A, ARDUINI F, SANTINI D, ANDREONI F, MAGNANI M (2003). AN ANALYSIS OF CDH1-160 C/A PROMOTER POLYMORPHISM AND THE RISK OF DIFFUSE GASTRIC CANCER IN ITALY. In: EUROPEAN JOURNAL OF CANCER SUPPLEMENTS, vol. 1, NO. 5 RUZZO A, GRAZIANO F, COSTAGLIOLA A, TESTA E,

24 ANDREONI F, ARDUINI F, ANTOLINI A, BEARZI I, DE GAETANO A, MAGNANI M (2003). ANALYSIS OF G/A SNP CHANGE AT POSITION 2494 IN THE E-CADHERIN GENE IN ITALIAN PATIENTS WITH SPORADIC, DIFFUSE GASTRIC CANCER. In: EUROPEAN JOURNAL OF CANCER SUPPLEMENTS, vol. 1, NO. 5, p. S63 HUMAR B, GRAZIANO F, CASCINU S, CATALANO V, RUZZO A, MAGNANI M., TORO T, BURCHILL T, FUTSCHIK ME, MERRIMAN T, GUILFORD P (2002). Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. ONCOGENE, vol. 21; p , ISSN: A. INNOCETA, L. GALLUZZI, RUZZO A, F. ANDREONI, L. CHIARANTINI, M. MAGNANI (2002). Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells. MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 231; p , ISSN: MAGNANI M., BIANCHI M, RUZZO A, ANDREONI F, SERAFINI G, BOLOGNESI M (2002). Hexokinase. In: JOHN WILEY SONS, INC.. Wiley Encyclopedia of Molecular Medicine. vol. 5, p , GRAZIANO F, RUZZO A, BEARZI I, TESTA E, TRAVAGLINO L, MAGNANI M, LAI V, GUILFORD P (2001). Homozigous Nucleotide Change In The E-Cadherin Gene (CDH-1) Promoter. A New Germline Mutation For Diffuse Gastric Cancer (DGC) Susceptibility?. In: atti congresso VERONA, NOVEMBRE ANDREONI F, RUZZO A, BERTOZZINI E, MAGNANI M (2001). SEQUENCE VARIATION IN THE BOVINE HEXOKINASE TYPE I GENE. In: atti del congresso. L AQUILA, SETTEMBRE ANDREONI F, RUZZO A, MAGNANI M (2000). Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mrna. BIOCHIMICA ET BIOPHYSICA ACTA, vol (1-2); p , ISSN: ANDREONI F, RUZZO A, MAGNANI M (1999). Structure Of The 5 Part Of The Human Hexokinase Tyope I (HK1) Gene And Identification Of An Additional Testis-Specific

25 HK1 mrna. In: atti congresso. BOLOGNA, 8-11MAGGIO, p. E 17 ANDREONI F, RUZZO A, BIANCHI M, SERAFINI G, BARTOLUCCI E, PALMA F, MAGNANI M (1998). Identification And Characterization Of A Human Red Blood Cell-Specific Hexokinase Isozyme. In: atti congresso. PARMA, 1-3 LUGLIO, p. 69 ANDREONI F, RUZZO A, BIANCHI M, SERAFINI G, BARTOLUCCI E, PALMA F, MAGNANI M (1998). Identificazione E Caratterizzazione Di Un Isoenzima Dell esocinasi Eritroide-Specifico. In: atti congresso. ROMA, 29 MAGGIO ANDREONI F, RUZZO A, MAGNANI M, BARI SETTEMBRE OTTOBRE (1998). IDENTIFICATION OF AN ADDITIONAL TESTIS-SPECIFIC MRNA FOR A UNIQUE HUMAN HEXOKINASE TYPE I. In: atti congresso. BARI, 27 SETTEMBRE 1 OTTOBRE RUZZO A, ANDREONI F, MAGNANI M (1998). Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region. BIOCHEMICAL JOURNAL, vol. 331; p , ISSN: RUZZO A, ANDREONI F, MAGNANI M (1998). An erythroid-specific exon is present in the human hexokinase gene. BLOOD, vol. 91 (1); p , ISSN: RUZZO A, ANDREONI F, MAGNANI M (1997). Structure of the human hexokinase type I gene. BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 25(1); p. 70s-, ISSN: ANDREONI F, RUZZO A, MAGNANI M (1997). Structure Of The Human Hexokinase Type I Gene And Partial 5 -Flanking Region. In: atti congresso. ANCONA, SETTEMBRE COLOSIMO A, CALABRESE G, GENNARELLI M, RUZZO A, SANGIUOLO F, MAGNANI M, PALKA G, NOVELLI G, DALLAPICCOLA B (1996). Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by

26 somatic cell hybrids and in situ hybridization. CYTOGENETICS AND CELL GENETICS, vol. 74(3); p , ISSN: INNOCETA A. M, RUZZO A, ANDREONI F, CASABIANCA A, CHIARANTINI L, ANTONELLI A, BRANDI G, MAGNANI M (1995). Molecular Basis Of The 2',3'-Dideoxycytidine Induced Drug-Resistance In Human Cells. In: atti congresso. Torino, settembre, p. P 138 Ninfali P, Baronciani L, RUZZO A, Fortini C, Amadori E, Dall'ara G, Magnani M, Beutler E (1993). Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district. HUMAN GENETICS, vol. 92; p , ISSN: RUZZO A, NINFALI P, MAGNANI M (1993). Glucose-6-phosphate dehydrogenase nucleotide 1311 polymorphism in central Italy (Marche Region)., vol. 47(1); p NINFALI P., L. BARONCIANI, RUZZO A, C. FORTINI, E. AMADORI, G. DALL'ARA, MAGNANI M., E. BEUTLER. (1993). Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district. HUMAN GENETICS, vol. 92; p , ISSN: RUZZO A, ANDREONI F, MAGNANI M (1992). Frequenza Del Polimorfismo 1311 Del Gene G6PD Nella Popolazione Marchigiana. In: atti del congresso. FERRARA, 5-6 OCTOBER NOVELLI G, MANDICH P, RUZZO A, MANNELLO F, AJMAR F, DALLAPICCOLA B (1990). SPECIFIC ENZYMATIC AMPLIFICATION OF A DNA REGION CLOSELY ASSOCIATED WITH HUNTINGTON CHOREA. BOLLETTINO DELLA SOCIETA' ITALIANA DI BIOLOGIA SPERIMENTALE, vol. 66(5); p , ISSN: GASPARINI P, NOVELLI G, ESTIVILL X, OLIVIERI D, SAVOIA A, RUZZO A, NUNES V, BORGO G, ANTONELLI M, WILLIAMSON R, ET AL (1990). The genotype of a new linked DNA marker, MP6d-9, is related to the clinical course of cystic fibrosis. JOURNAL OF MEDICAL GENETICS, vol. 27(1); p , ISSN:

27 ESTIVILL X, GASPARINI P, NOVELLI G, CASALS T, NUNES V, GALLANO P, SAVOIA A, RUZZO A, DALLAPICCOLA B, PIGNATTI PF (1989). Linkage disequilibrium for DNA haplotypes near the cystic fibrosis locus in two south European populations. HUMAN GENETICS, vol. 83(2); p , ISSN: RUZZO A, NOVELLI G, DALLAPICCOLA B (1989). Fibrosi Cistica: Aspetti Clinici E Diagnostici. PATOLOGO CLINICO, vol. 1; p , ISSN: GENNARELLI M, NOVELLI G, RUZZO A, GRIANTI F, DALLAPICCOLA B (1989). [Construction of an apparatus for pulsed field electrophoresis for the analysis of high molecular weight DNA]. BOLLETTINO DELLA SOCIETA' ITALIANA DI BIOLOGIA SPERIMENTALE, vol. 65(1); p , ISSN: NOVELLI G, GASPARINI P, ESTIVILL X, RUZZO A, SAVOIA A, NUNES V, CASALS T, PIGNATTI PF, DALLAPICCOLA B SPECIFIC DNA AMPLIFICATION IN THE PRENATAL DIAGNOSIS OF CYSTIC FIBROSIS (1989). Specific DNA Amplification In The Prenatal Diagnosis Of Cystic Fibrosis. In: atti congresso. Praga, June 15-18, p. 103 GASPARINI P, NOVELLI G, ESTIVILL X, ROSSI G, BORGO G MASTELLA G ANTONELLI M, SAVOIA A, RUZZO A, PIGNATTI PF (1989). Prediction Of CF Clinical Outcome By MP6d-9 Haplotype Analysis. In: atti congresso. Praga, June 15-18, p. 131 NUNES V, GASPARINI P, RUZZO A, CASALS T, GALLANO P, SAVOIA A, RUZZOA, DALLAPICCOLA B, PIGNATTI PF, ESIVILL X (1989). : Polymorphic DNA Haplotypes Near The Cystic Fibrosis Locus In Two South European Population (Spain And Italy). In: atti congresso. Praga, June 15-18, p. 151 NOVELLI G, RUZZO A, MANNELLO F, DALLAPICCOLA B (1989). Amplificazione Enzimatica Specifica Del DNA Nella Diagnosi Preclinica,Clinica E Prenatale Di Malattie Genetiche. In: atti congresso. FIRENZE, MAY, p. 152 DALLAPICCOLA B, NOVELLI G, MANNELLO F, RUZZO A,

28 POTENZA L, GENNARELLI M, DI RENZO GC, COSMI EV, PACHÌ A (1988). Improved Prenatal Biochemical Predictivity Of Cystic Fibrosis By Kinetic And Electrophoretic Analysis Of Alkaline Phosphatase Isoenzymes. In: Proceeding XI European Congress of Perinatal Medicine, ED CIC INTERNAZIONALI;. ROMA, APRIL, p NOVELLI G, POTENZA L, RUZZO A, GENNARELLI M, BOSMAN C, DALLAPICCOLA B (1988). Polymorphic DNA Markers And Prenatal Diagnosis In Adult Polycistic Kidney Disease DNA Analysis Of Genetic Diseases : State Of The Art In Italy,. In: PIRASTU M,CAMASCHELLA C,MORPURGO G,POLSINELLI M EDTS MILANO, p NOVELLI G, GASPARINI P, RUZZO A, SAVOIA A, PIGNATTI P, DALLAPICCOLA B (1988). Analisi molecolare e diagnosi prenatale di fibrosi cistica con polimorfismi di restrizione al locus D7S23. In: atti congresso. ANCONA, SEPTEMBER 12-13, p. 162 NOVELLI G, POTENZA L, RUZZO A, DALLAPICCOLA B (1987). Analisi Molecolare Di 20 Famiglie Nucleari Con Probando Affetto Da Fibrosi Cistica. In: atti congresso. SIENA, OTTOBRE 1987, p. 121 G. NOVELLI, L. POTENZA, RUZZO A, B. DALLAPICCOLA (1987). Polymorphic DNA markers linked to cystic fibrosis locus in 20 Italian nuclear families. GENE GEOGRAPHY, vol. 1 (3); p , ISSN: X NOVELLI G, MANNELLO F, RUZZO A, LUZI G, POMILI G, DI RENZO GC, COSMI EV, DALLAPICCOLA B (1987). Analisi Elettroforetica Delle Proteinasi Nei Villi Coriali Umani. In: ED CIC atti congresso. PERUGIA, may, p